Michelle Allen-Sharpley
Neurology with Special Qualifications in Child Neurology · West Hollywood, CANPI 1235523473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $251 and has fallen 63.7% since, to $91 in 2025. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in CA, where the typical reported total is $1,230.
Across 10 payments — averaging $68.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$144
- UCB, Inc.$134
- AstraZeneca$122
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$117
- Neurelis, Inc.$108
- Catalyst Pharmaceuticals, Inc.$31
- plus $29 from 3 others
Across 1 payment — averaging $24.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$24
What the payments were for
- Food & beverage$684100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $144 |
| UCB, Inc. | 1 | $134 |
| AstraZeneca | 1 | $122 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $117 |
| Neurelis, Inc. | 1 | $108 |
| Catalyst Pharmaceuticals, Inc. | 1 | $31 |
| Genentech, Inc. | 1 | $15 |
| Life Molecular Imaging Ltd | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$685 in reported general payments places this provider in the 40th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in West Hollywood
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Akash VirupakshaiahSan Francisco$94K
- Brittany PassiakSan Diego$90K
- Kevin ShapiroMadera$84K
- Terence SangerStanford$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.